Nisreen Alwan: What is long COVID?
Long COVID is often described as a prolonged period of illness following infection with SARS-CoV-2, but what is the official definition, what are the symptoms and who is most at risk?
In this interview, we speak with Prof. Nisreen Alwan (University of Southampton, Southampton UK), a Professor in Public Health with personal experience of long COVID, and someone who has spent the last two years at the forefront of the pandemic as an advocate raising awareness of the condition.
- What is the NICE definition of long COVID and what are its symptoms? (0:23)
- How does long COVID differ from other post-viral infection syndromes? (1:17)
- What do we know about the trajectory of long COVID symptoms? (2:02)
- Who is most at risk of long COVID? (2:45)
Disclosures: Prof. Nisreen Alwan has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Share this Video
Related Videos In COVID-19
Molnupiravir, an oral antiviral against SARS-CoV-2: Chris Butler, ECCMID 2023
Molnupiravir, an oral antiviral against SARS-CoV-2 was first granted emergency use authorisation in 2021 to reduce the risk of hospitalisation and death in mild to moderate COVID-19 with increased risk of developing severe disease. We were delighted to speak with Prof. Chris Butler (University of Oxford, Oxford, UK) to discuss the mechanism of action of […]
PANORAMIC trial – Molnupiravir efficacy in adults with COVID-19 at increased risk of adverse outcomes: Chris Butler, ECCMID 2023
PANORAMIC (ISRCTN30448031) was a multicentre, open-label, randomized controlled trial investigating novel treatments for COVID-19 in the UK. We were delighted to speak with Prof. Chris Butler (University of Oxford, Oxford, UK) to discuss the PANORAMIC study results, and how these insights will optimise the use of molnupiravir in clinical practice. Catch up: Interview with Prof. […]
COVID-19 vaccine development, updates and advances: Christoph Spinner, ECCMID 2023
The COVID-19 pandemic brought about the accelerated development of vaccinations to protect against variants of SARS-CoV-2, recently new targets of broad protection against potential future variants have been outlined and numerous vaccine candidates are in pre-clinical and clinical development. It was a pleasure to speak with Editorial Board member Dr. Christoph Spinner (Technical University of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!